Business
Clene Reports First Quarter 2025 Financial Results and Recent Operating Highlights
Clene preparing for upcoming meeting in the second quarter with the U.S. Food and Drug Administration (FDA) to reach agreement on its statistical analysis plan (SAP) regarding analysis of neurofilament light chain (NfL) biomarker dataClene collecting NfL biomarker data from its large National Institute of Health (NIH)-sponsored Expanded Access Protocol (EAP), for evaluation in the third quarter to satisfy the FDA recommendation for additional NfL dataClene reported new data supporting the remyel
About this update from Clene Inc.
[{"type":"image","alt":"Clene Inc.","displaySize":"","headline":null,"caption":"Clene Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":72,"url":"https://media.zenfs.com/en/globenewswire.com/6ecbc5bc1ea840a1a7b45cd42deb4188"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/dqllcqG43QFquU0vfLNVhA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTEwMTtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/6ecbc5bc1ea840a1a7b45cd42deb4188","width":300,"height":72}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"Clene preparing for upcoming meeting in the second quarter with the U.S. Food and Drug Administration (FDA) to reach agreement on its statistical analysis plan (SAP) regarding analysis of neurofilament light chain (NfL) biomarker data","length":234,"tagName":"p"}]},{"val":[{"type":"text","content":"Clene collecting NfL biomarker data from its large National Institute of Health (NIH)-sponsored Expanded Access Protocol (EAP), for evaluation in the third quarter to satisfy the FDA recommendation for additional NfL data","length":221,"tagName":"p"}]},{"val":[{"type":"text","content":"Clene reported new data supporting the remyelination and neuronal repair associated with CNM-Au8® treatment in a late-breaking science session at the American Academy of Neurology (AAN) 2025 Annual Meeting","length":205,"tagName":"p"}]},{"val":[{"type":"text","content":"Clene released new data from a cross-regimen analysis of HEALEY ALS Platform Trial, showing that CNM-Au8 significantly extends survival in patients with ALS","length":156,"tagName":"p"}]},{"val":[{"type":"text","content":"Clene planning to submit a New Drug Application (NDA) in the fourth quarter of 2025 for potential Accelerated Approval of CNM-Au8 in ALS","length":141,"tagName":"p"}]},{"val":[{"type":"text","content":"Cash and cash equivalents of $9.8 million as of March 31, 2025, providing cash runway into the third quarter of 2025","length":116,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":1073,"olType":false},{"type":"text","content":"SALT LAKE CITY, May 07, 2025 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., a late clinical-stage biopharmaceutical company focused on revolutionizing the treatment of neurodegenerative diseases, including ...